38 / 62
*Only PD-L1-positive patients.
Ott PA, et al.
J Clin Oncol
. 2017
0
4
8
12
16
20
24
0
20
40
60
80
100
T im e , m o n th s
P r o g r e s s io n -F r e e S u r v iv a l, %
Num ber at risk 24
8
6
2
4
2
0
9
6
5
2
2
0
4
8
12
16
20
24
0
20
40
60
80
100
T im e , m o n th s
O v e r a ll S u r v iv a l, %
Num ber at risk 24
17
14
4
8
4
0
20
14
9
4
6
4
28.6% 23.8%
66.0% 37.7%
PFS
OS
Study phase
Line of
treatment
Regimen
Patients
ORR, % DOR, mo
PFS, mo
OS, mo
1b*
2
PEMBRO 10 mg/kg
24
33.3
19.4
1.9
9.7